
    
      The primary objective of this study is to show that safety parameters are similar, when
      delivering insulin subcutaneously in subjects with type I diabetes using the InsuPatch device
      along with the Medtronic Minimed Paradigm insulin infusion pump and the Medtronic Minimed
      Quick-SetÂ® infusion set compared to subcutaneous insulin delivered with the above mentioned
      equipment, without the InsuPatch device.

      The participation of each subject in this study will be up to seven months and will include
      three phases: one week Run in phase , 3 months with device use and 3 months without device
      use. Study will include 4 clinic visits and bi weekly calls. During the entire study the
      subjects will be requested to preform at least 5 blood glucose self measurements and record
      results in a logbook.At each visit blood will be drawn for HBA1C test.
    
  